+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chronic Pain Treatment Market Research Report: By Product, Indication, Application, Distribution Channel, and End User - Global Industry Revenue Estimation and Demand Forecast to 2030

  • ID: 5201160
  • Report
  • December 2021
  • Region: Global
  • 539 Pages
  • Prescient & Strategic Intelligence Private Limited

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca plc
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Medtronic plc
The global chronic pain treatment market valued $80,766.6 million in 2020, from where it is set to reach $162,175.2 million by 2030, at a 7.2% CAGR between 2020 and 2030. This will be majorly because of the geriatric population, which, as per the United Nations (UN), will increase from 727 million in 2020 to 1.5 billion by 2050. With age, people become prone to several health issues, including chronic pain because of arthritis, muscle strain, posture issues, and other reasons.





Most patients purchase drugs and devices for the treatment of chronic pain associated with musculoskeletal conditions, such as osteoarthritis, rheumatoid arthritis, and fibromyalgia. For instance, in 2017, 8.7 million osteoarthritis patients in the age group of 45 and above were treated in the U.K., says Arthritis Research U.K. Hence, on account of the rising prevalence of bone and muscle diseases, the demand for chronic pain treatment products is surging.

Key Findings of Chronic Pain Treatment Market Report

Drugs witness the higher sales due to the surging number of people with lower back pain, migraine pain or severe headache, and facial pain. This is itself a result of the sedentary lifestyle, increasing surgery volume, and booming geriatric population.

In the coming years, drugs and devices will be procured in the highest volumes to treat chronic cancer pain, due to the rising incidence of this disease. As tumors tear through tissues, muscles, bones, skin, and blood vessels, they cause extreme pain.

Revenue generation for chronic pain treatment market players through direct distribution channels is set to rise faster in the coming years. This way, at-home patients participating in clinical trials get faster access to treatments.

The COVID-19 pandemic has boosted the demand for chronic pain treatment drugs and devices by creating stress among people with pre-existing health issues, which ended up causing them long-term pain.

North America witnesses the highest sale of these products because of the high health awareness, developed medical infrastructure, and increasing cases of chronic diseases, such as cancer and heart diseases.

Seeing the rising number of people with chronic pain, healthcare companies are bringing about innovations in wearable medical devices and non-opioid pain medication.

The fastest chronic pain treatment market growth is expected to be witnessed in Asia-Pacific (APAC), which, being the most-populated region, is home to a huge patient pool. Thus, the growing geriatric population and number of people with chronic diseases, combined with the increasing awareness on chronic pain, offer lucrative opportunities to market players.

Key companies in the chronic pain treatment market include Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline plc, Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Novartis AG, AstraZeneca plc, Johnson & Johnson, Bristol-Myers Squibb Company, Sanofi S.A., and Becton, Dickinson and Company. To gain the upper hand, they are engaging in partnerships, product launches, and partnerships.
Frequently Asked Questions about the Chronic Pain Treatment Market

What is the estimated value of the Chronic Pain Treatment Market?

The Chronic Pain Treatment Market was estimated to be valued at $80766.6 Million in 2020.

What is the growth rate of the Chronic Pain Treatment Market?

The growth rate of the Chronic Pain Treatment Market is 7.2%, with an estimated value of $162175.2 Million by 2030.

What is the forecasted size of the Chronic Pain Treatment Market?

The Chronic Pain Treatment Market is estimated to be worth $162175.2 Million by 2030.

Who are the key companies in the Chronic Pain Treatment Market?

Key companies in the Chronic Pain Treatment Market include Eli Lilly and Company, GlaxoSmithKline plc, Pfizer Inc., Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Novartis AG, Johnson & Johnson and Bristol.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca plc
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Medtronic plc

Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Research Scope
1.3.1 Market Segmentation by Product
1.3.2 Market Segmentation by Indication
1.3.3 Market Segmentation by Application
1.3.4 Market Segmentation by Distribution Channel
1.3.5 Market Segmentation by End User
1.3.6 Market Segmentation by Region
1.3.7 Analysis Period
1.3.8 Market Data Reporting Unit
1.3.8.1 Value
1.4 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 By region
2.2.1.2 By industry participant
2.2.1.3 By company type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Assumptions for the Study
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1 Definition of Market Segments
4.1.1 By Product
4.1.1.1 Drugs
4.1.1.1.1 Opioids
4.1.1.1.2 NSAIDs
4.1.1.1.3 Anticonvulsants
4.1.1.1.4 Antidepressants
4.1.1.1.5 Others
4.1.2 By Devices
4.1.2.1 Neurostimulation devices
4.1.2.1.1 SCS
4.1.2.1.2 TENS
4.1.2.1.3 Others
4.1.2.2 Analgesic infusion pumps
4.1.2.3 Ablation devices
4.1.2.3.1 Radiofrequency ablation devices
4.1.2.3.2 Cryoablation devices
4.1.3 By Indication
4.1.3.1 Neuropathic pain
4.1.3.2 Arthritis pain
4.1.3.3 Chronic back pain
4.1.3.4 Cancer pain
4.1.3.5 Migraine
4.1.3.6 Fibromyalgia
4.1.3.7 Others
4.1.4 By Application
4.1.4.1 Musculoskeletal
4.1.4.2 Neuropathy
4.1.4.3 Oncology
4.1.4.4 Others
4.1.5 By Distribution channel
4.1.5.1 Direct
4.1.5.2 Indirect
4.1.6 By End User
4.1.6.1 Hospitals
4.1.6.2 Clinics
4.1.6.3 Nursing homes
4.1.6.4 Research centers & universities
4.1.6.5 Others
4.2 Market Dynamics
4.2.1 Trends
4.2.1.1 Innovations in the field of pain management
4.2.1.2 Increasing number of product approvals
4.2.2 Drivers
4.2.2.1 Increasing government support for chronic pain management
4.2.2.2 Growing geriatric population
4.2.2.3 Surging prevalence of chronic health conditions
4.2.3 Impact Analysis of Drivers on Market Forecast
4.2.4 Restraints
4.2.4.1 Side effects associated with pain management drugs and devices
4.2.4.2 Product recalls
4.2.4.3 Patent expiry of blockbuster chronic pain treatment drugs
4.2.4.4 Increasing usage of opioids and antidepressants
4.2.5 Impact Analysis of Restraints on Market Forecast
4.3 Porter’s Five Forces Analysis
4.4 Impact of COVID-19
Chapter 5. Industry Insights
5.1 Pricing and Reimbursement Scenario
5.1.1 Pricing
5.1.2 Reimbursement Scenario
5.1.2.1 U.S.
5.1.2.2 Canada
5.1.2.3 Europe
5.1.2.3.1 Italy
5.1.2.3.2 Germany
5.1.2.3.3 U.K.
5.1.2.4 Japan
5.1.2.5 Australia
5.2 Research Funding and Government Initiatives
5.3 Pipeline Drugs for Chronic Pain
5.4 Key Products Expected to be Launched
5.5 Treatment
Chapter 6. Epidemiology Analysis
6.1 Number of People Reported with Chronic Pain in North America
6.1.1 U.S.
6.1.1.1 Patients visited healthcare facilities for the management of chronic pain in U.S.
6.1.1.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in U.S.
6.1.2 Canada
6.1.2.1 Patients visited healthcare facilities for the management of chronic pain in Canada
6.1.2.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Canada
6.2 Number of People Reported with Chronic Pain in Europe
6.2.1 Germany
6.2.1.1 Patients visited healthcare facilities for the management of chronic pain in Germany
6.2.1.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Germany
6.2.2 France
6.2.2.1 Patients visited healthcare facilities for the management of chronic pain in France
6.2.2.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in France
6.2.3 U.K.
6.2.3.1 Patients visited healthcare facilities for the management of chronic pain in U.K.
6.2.3.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in U.K.
6.2.4 Italy
6.2.4.1 Patients visited healthcare facilities for the management of chronic pain in Italy
6.2.4.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Italy
6.2.5 Spain
6.2.5.1 Patients visited healthcare facilities for the management of chronic pain in Spain
6.2.5.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Spain
6.2.6 Netherlands
6.2.6.1 Patients visited healthcare facilities for the management of chronic pain in Netherlands
6.2.6.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Netherlands
6.2.7 Russia
6.2.7.1 Patients visited healthcare facilities for the management of chronic pain in Russia
6.2.7.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Russia
6.2.8 Sweden
6.2.8.1 Patients visited healthcare facilities for the management of chronic pain in Sweden
6.2.8.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Sweden
6.2.9 Switzerland
6.2.9.1 Patients visited healthcare facilities for the management of chronic pain in Switzerland
6.2.9.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Switzerland
6.3 Number of People Reported with Chronic Pain in APAC
6.3.1 Japan
6.3.1.1 Patients visited healthcare facilities for the management of chronic pain in Japan
6.3.1.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Japan
6.3.2 China
6.3.2.1 Patients visited healthcare facilities for the management of chronic pain in China
6.3.2.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in China
6.3.3 India
6.3.3.1 Patients visited healthcare facilities for the management of chronic pain in India
6.3.3.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in India
6.3.4 Australia
6.3.4.1 Patients visited healthcare facilities for the management of chronic pain in Australia
6.3.4.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Australia
6.3.5 South Korea
6.3.5.1 Patients visited healthcare facilities for the management of chronic pain in South Korea
6.3.5.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in South Korea
6.4 Number of People Reported with Chronic Pain in LATAM
6.4.1 Brazil
6.4.1.1 Patients visited healthcare facilities for the management of chronic pain in Brazil
6.4.1.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Brazil
6.4.2 Mexico
6.4.2.1 Patients visited healthcare facilities for the management of chronic pain in Mexico
6.4.2.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Mexico
6.5 Number of People Reported with Chronic Pain in MEA
6.5.1 Saudi Arabia
6.5.1.1 Patients visited healthcare facilities for the management of chronic pain in Saudi Arabia
6.5.1.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Saudi Arabia
6.5.2 South Africa
6.5.2.1 Patients visited healthcare facilities for the management of chronic pain in South Africa
6.5.2.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in South Africa
Chapter 7. Global Market Size and Forecast
7.1 By Product
7.1.1 Chronic Pain Drugs Market, by Type
7.1.2 Chronic Pain Devices Market, by Type
7.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
7.1.2.2 Ablation devices market for chronic pain treatment, by type
7.2 By Indication
7.3 By Application
7.4 By Distribution Channel
7.5 By End User
7.6 By Region
Chapter 8. North America Market Size and Forecast
8.1 By Product
8.1.1 Chronic Pain Drugs Market, by Type
8.1.2 Chronic Pain Devices Market, by Type
8.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
8.1.2.2 Ablation devices market for chronic pain treatment, by type
8.2 By Indication
8.3 By Application
8.4 By Distribution Channel
8.5 By End User
8.6 By Country
8.6.1 U.S. Market Size and Forecast
8.6.1.1 By product
8.6.1.1.1 Chronic pain drugs market, by type
8.6.1.1.2 Chronic pain devices market, by type
8.6.1.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
8.6.1.1.2.2 Ablation devices market for chronic pain treatment, by type
8.6.1.2 By indication
8.6.1.3 By application
8.6.1.4 By distribution channel
8.6.1.5 By end user
8.6.2 Canada Market Size and Forecast
8.6.2.1 By product
8.6.2.1.1 Chronic pain drugs market, by type
8.6.2.1.2 Chronic pain devices market, by type
8.6.2.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
8.6.2.1.2.2 Ablation devices market for chronic pain treatment, by type
8.6.2.2 By indication
8.6.2.3 By application
8.6.2.4 By distribution channel
8.6.2.5 By end user
Chapter 9. Europe Market Size and Forecast
9.1 By Product
9.1.1 Chronic Pain Drugs Market, by Type
9.1.2 Chronic Pain Devices Market, by Type
9.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
9.1.2.2 Ablation devices market for chronic pain treatment, by type
9.2 By Indication
9.3 By Application
9.4 By Distribution Channel
9.5 By End User
9.6 By Country
9.6.1 Germany Market Size and Forecast
9.6.1.1 By product
9.6.1.1.1 Chronic pain drugs market, by type
9.6.1.1.2 Chronic pain devices market, by type
9.6.1.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
9.6.1.1.2.2 Ablation devices market for chronic pain treatment, by type
9.6.1.2 By indication
9.6.1.3 By application
9.6.1.4 By distribution channel
9.6.1.5 By end user
9.6.2 France Market Size and Forecast
9.6.2.1 By product
9.6.2.1.1 Chronic pain drugs market, by type
9.6.2.1.2 Chronic pain devices market, by type
9.6.2.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
9.6.2.1.2.2 Ablation devices market for chronic pain treatment, by type
9.6.2.2 By indication
9.6.2.3 By application
9.6.2.4 By distribution channel
9.6.2.5 By end user
9.6.3 U.K. Market Size and Forecast
9.6.3.1 By product
9.6.3.1.1 Chronic pain drugs market, by type
9.6.3.1.2 Chronic pain devices market, by type
9.6.3.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
9.6.3.1.2.2 Ablation devices market for chronic pain treatment, by type
9.6.3.2 By indication
9.6.3.3 By application
9.6.3.4 By distribution channel
9.6.3.5 By end user
9.6.4 Italy Market Size and Forecast
9.6.4.1 By product
9.6.4.1.1 Chronic pain drugs market, by type
9.6.4.1.2 Chronic pain devices market, by type
9.6.4.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
9.6.4.1.2.2 Ablation devices market for chronic pain treatment, by type
9.6.4.2 By indication
9.6.4.3 By application
9.6.4.4 By distribution channel
9.6.4.5 By end user
9.6.5 Spain Market Size and Forecast
9.6.5.1 By product
9.6.5.1.1 Chronic pain drugs market, by type
9.6.5.1.2 Chronic pain devices market, by type
9.6.5.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
9.6.5.1.2.2 Ablation devices market for chronic pain treatment, by type
9.6.5.2 By indication
9.6.5.3 By application
9.6.5.4 By distribution channel
9.6.5.5 By end user
9.6.6 Netherlands Market Size and Forecast
9.6.6.1 By product
9.6.6.1.1 Chronic pain drugs market, by type
9.6.6.1.2 Chronic pain devices market, by type
9.6.6.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
9.6.6.1.2.2 Ablation devices market for chronic pain treatment, by type
9.6.6.2 By indication
9.6.6.3 By application
9.6.6.4 By distribution channel
9.6.6.5 By end user
9.6.7 Russia Market Size and Forecast
9.6.7.1 By product
9.6.7.1.1 Chronic pain drugs market, by type
9.6.7.1.2 Chronic pain devices market, by type
9.6.7.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
9.6.7.1.2.2 Ablation devices market for chronic pain treatment, by type
9.6.7.2 By indication
9.6.7.3 By application
9.6.7.4 By distribution channel
9.6.7.5 By end user
9.6.8 Sweden Market Size and Forecast
9.6.8.1 By product
9.6.8.1.1 Chronic pain drugs market, by type
9.6.8.1.2 Chronic pain devices market, by type
9.6.8.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
9.6.8.1.2.2 Ablation devices market for chronic pain treatment, by type
9.6.8.2 By indication
9.6.8.3 By application
9.6.8.4 By distribution channel
9.6.8.5 By end user
9.6.9 Switzerland Market Size and Forecast
9.6.9.1 By product
9.6.9.1.1 Chronic pain drugs market, by type
9.6.9.1.2 Chronic pain devices market, by type
9.6.9.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
9.6.9.1.2.2 Ablation devices market for chronic pain treatment, by type
9.6.9.2 By indication
9.6.9.3 By application
9.6.9.4 By distribution channel
9.6.9.5 By end user
Chapter 10. APAC Market Size and Forecast
10.1 By Product
10.1.1 Chronic Pain Drugs Market, by Type
10.1.2 Chronic Pain Devices Market, by Type
10.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
10.1.2.2 Ablation devices market for chronic pain treatment, by type
10.2 By Indication
10.3 By Application
10.4 By Distribution Channel
10.5 By End User
10.6 By Country
10.6.1 Japan Market Size and Forecast
10.6.1.1 By product
10.6.1.1.1 Chronic pain drugs market, by type
10.6.1.1.2 Chronic pain devices market, by type
10.6.1.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
10.6.1.1.2.2 Ablation devices market for chronic pain treatment, by type
10.6.1.2 By indication
10.6.1.3 By application
10.6.1.4 By distribution channel
10.6.1.5 By end user
10.6.2 China Market Size and Forecast
10.6.2.1 By product
10.6.2.1.1 Chronic pain drugs market, by type
10.6.2.1.2 Chronic pain devices market, by type
10.6.2.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
10.6.2.1.2.2 Ablation devices market for chronic pain treatment, by type
10.6.2.2 By indication
10.6.2.3 By application
10.6.2.4 By distribution channel
10.6.2.5 By end user
10.6.3 India Market Size and Forecast
10.6.3.1 By product
10.6.3.1.1 Chronic pain drugs market, by type
10.6.3.1.2 Chronic pain devices market, by type
10.6.3.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
10.6.3.1.2.2 Ablation devices market for chronic pain treatment, by type
10.6.3.2 By indication
10.6.3.3 By application
10.6.3.4 By distribution channel
10.6.3.5 By end user
10.6.4 Australia Market Size and Forecast
10.6.4.1 By product
10.6.4.1.1 Chronic pain drugs market, by type
10.6.4.1.2 Chronic pain devices market, by type
10.6.4.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
10.6.4.1.2.2 Ablation devices market for chronic pain treatment, by type
10.6.4.2 By indication
10.6.4.3 By application
10.6.4.4 By distribution channel
10.6.4.5 By end user
10.6.5 South Korea Market Size and Forecast
10.6.5.1 By product
10.6.5.1.1 Chronic pain drugs market, by type
10.6.5.1.2 Chronic pain devices market, by type
10.6.5.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
10.6.5.1.2.2 Ablation devices market for chronic pain treatment, by type
10.6.5.2 By indication
10.6.5.3 By application
10.6.5.4 By distribution channel
10.6.5.5 By end user
Chapter 11. LATAM Market Size and Forecast
11.1 By Product
11.1.1 Chronic Pain Drugs Market, by Type
11.1.2 Chronic Pain Devices Market, by Type
11.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
11.1.2.2 Ablation devices market for chronic pain treatment, by type
11.2 By Indication
11.3 By Application
11.4 By Distribution Channel
11.5 By End User
11.6 By Country
11.6.1 Brazil Market Size and Forecast
11.6.1.1 By product
11.6.1.1.1 Chronic pain drugs market, by type
11.6.1.1.2 Chronic pain devices market, by type
11.6.1.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
11.6.1.1.2.2 Ablation devices market for chronic pain treatment, by type
11.6.1.2 By indication
11.6.1.3 By application
11.6.1.4 By distribution channel
11.6.1.5 By end user
11.6.2 Mexico Market Size and Forecast
11.6.2.1 By product
11.6.2.1.1 Chronic pain drugs market, by type
11.6.2.1.2 Chronic pain devices market, by type
11.6.2.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
11.6.2.1.2.2 Ablation devices market for chronic pain treatment, by type
11.6.2.2 By indication
11.6.2.3 By application
11.6.2.4 By distribution channel
11.6.2.5 By end user
Chapter 12. MEA Market Size and Forecast
12.1 By Product
12.1.1 Chronic Pain Drugs Market, by Type
12.1.2 Chronic Pain Devices Market, by Type
12.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
12.1.2.2 Ablation devices market for chronic pain treatment, by type
12.2 By Indication
12.3 By Application
12.4 By Distribution Channel
12.5 By End User
12.6 By Country
12.6.1 Saudi Arabia Market Size and Forecast
12.6.1.1 By product
12.6.1.1.1 Chronic pain drugs market, by type
12.6.1.1.2 Chronic pain devices market, by type
12.6.1.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
12.6.1.1.2.2 Ablation devices market for chronic pain treatment, by type
12.6.1.2 By indication
12.6.1.3 By application
12.6.1.4 By distribution channel
12.6.1.5 By end user
12.6.2 South Africa Market Size and Forecast
12.6.2.1 By product
12.6.2.1.1 Chronic pain drugs market, by type
12.6.2.1.2 Chronic pain devices market, by type
12.6.2.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
12.6.2.1.2.2 Ablation devices market for chronic pain treatment, by type
12.6.2.2 By indication
12.6.2.3 By application
12.6.2.4 By distribution channel
12.6.2.5 By end user
Chapter 13. Competitive Landscape
13.1 Product Benchmarking of Key Players
13.2 Strategic Developments of Key Players
13.2.1 Partnerships, Collaborations, and Agreements
13.2.2 Mergers and Acquisitions
13.2.3 Product Launches and Approvals
Chapter 14. Company Profiles
14.1 Eli Lilly and Company
14.1.1 Business Overview
14.1.2 Product and Service Offerings
14.1.2.1 Marketed products
14.1.2.2 Pipeline products
14.1.3 Key Financial Summary
14.2 GlaxoSmithKline plc
14.2.1 Business Overview
14.2.2 Product and Service Offerings
14.2.2.1 Marketed products
14.2.2.2 Pipeline products
14.2.3 Key Financial Summary
14.3 Pfizer Inc.
14.3.1 Business Overview
14.3.2 Product and Service Offerings
14.3.2.1 Marketed products
14.3.2.2 Pipeline products
14.3.3 Key Financial Summary
14.4 Medtronic plc
14.4.1 Business Overview
14.4.2 Product and Service Offerings
14.4.3 Key Financial Summary
14.5 Abbott Laboratories
14.5.1 Business Overview
14.5.2 Product and Service Offerings
14.5.3 Key Financial Summary
14.6 Boston Scientific Corporation
14.6.1 Business Overview
14.6.2 Product and Service Offerings
14.6.3 Key Financial Summary
14.7 Novartis AG
14.7.1 Business Overview
14.7.2 Product and Service Offerings
14.7.2.1 Marketed products
14.7.2.2 Pipeline products
14.7.3 Key Financial Summary
14.8 Johnson & Johnson
14.8.1 Business Overview
14.8.2 Product and Service Offerings
14.8.2.1 Marketed products
14.8.2.2 Pipeline products
14.8.3 Key Financial Summary
14.9 AstraZeneca plc
14.9.1 Business Overview
14.9.2 Product and Service Offerings
14.9.2.1 Marketed products
14.9.2.2 Pipeline products
14.9.3 Key Financial Summary
14.10 Bristol-Myers Squibb Company
14.10.1 Business Overview
14.10.2 Product and Service Offerings
14.10.2.1 Marketed products
14.10.2.2 Pipeline products
14.10.3 Key Financial Summary
14.11 Becton, Dickinson and Company
14.11.1 Business Overview
14.11.2 Product and Service Offerings
14.11.3 Key Financial Summary
14.12 Sanofi S.A.
14.12.1 Business Overview
14.12.2 Product and Service Offerings
14.12.2.1 Marketed products
14.12.2.2 Pipeline products
14.12.3 Key Financial Summary
Chapter 15. Appendix
15.1 Abbreviations
15.2 Sources and References
15.3 Related Reports
List of Figures
Figure 1: RESEARCH SCOPE
Figure 2: RESEARCH METHODOLOGY
Figure 3: REGIONAL SPLIT OF PRIMARY AND SECONDARY RESEARCH
Figure 4: BREAKDOWN OF PRIMARY RESEARCH BY REGION
Figure 5: BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT
Figure 6: BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE
Figure 7: DATA TRIANGULATION APPROACH
Figure 8: GLOBAL CHRONIC PAIN TREATMENT MARKET SUMMARY
Figure 9: BARGAINING POWER OF BUYERS
Figure 10: BARGAINING POWER OF SUPPLIERS
Figure 11: INTENSITY OF RIVALRY
Figure 12: THREAT OF NEW ENTRANTS
Figure 13: THREAT OF SUBSTITUTES
Figure 14: TREATMENT PROCEDURES FOR CHRONIC PAIN
Figure 15: SNAPSHOT OF GLOBAL CHRONIC PAIN TREATMENT MARKET, BY PRODUCT, 2020
Figure 16: GLOBAL CHRONIC PAIN TREATMENT MARKET, BY PRODUCT, $M (2015-2030)
Figure 17: GLOBAL CHRONIC PAIN TREATMENT MARKET, BY INDICATION, $M (2015-2030)
Figure 18: GLOBAL CHRONIC PAIN TREATMENT MARKET, BY APPLICATION, $M (2015-2030)
Figure 19: GLOBAL CHRONIC PAIN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, $M (2015-2030)
Figure 20: GLOBAL CHRONIC PAIN TREATMENT MARKET, BY END USER, $M (2015-2030)
Figure 21: NORTH AMERICA CHRONIC PAIN TREATMENT MARKET SNAPSHOT
Figure 22: NORTH AMERICA CHRONIC PAIN TREATMENT MARKET, BY PRODUCT, $M (2015-2030)
Figure 23: NORTH AMERICA CHRONIC PAIN TREATMENT MARKET, BY INDICATION, $M (2015-2030)
Figure 24: NORTH AMERICA CHRONIC PAIN TREATMENT MARKET, BY APPLICATION, $M (2015-2030)
Figure 25: NORTH AMERICA CHRONIC PAIN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, $M (2015-2030)
Figure 26: NORTH AMERICA CHRONIC PAIN TREATMENT MARKET, BY END USER, $M (2015-2030)
Figure 27: NORTH AMERICA CHRONIC PAIN TREATMENT MARKET, BY COUNTRY, $M (2015-2030)
Figure 28: EUROPE CHRONIC PAIN TREATMENT MARKET SNAPSHOT
Figure 29: EUROPE CHRONIC PAIN TREATMENT MARKET, BY PRODUCT, $M (2015-2030)
Figure 30: EUROPE CHRONIC PAIN TREATMENT MARKET, BY INDICATION, $M (2015-2030)
Figure 31: EUROPE CHRONIC PAIN TREATMENT MARKET, BY APPLICATION, $M (2015-2030)
Figure 32: EUROPE CHRONIC PAIN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, $M (2015-2030)
Figure 33: EUROPE CHRONIC PAIN TREATMENT MARKET, BY END USER, $M (2015-2030)
Figure 34: EUROPE CHRONIC PAIN TREATMENT MARKET, BY COUNTRY, $M (2015-2030)
Figure 35: APAC CHRONIC PAIN TREATMENT MARKET SNAPSHOT
Figure 36: APAC CHRONIC PAIN TREATMENT MARKET, BY PRODUCT, $M (2015-2030)
Figure 37: APAC CHRONIC PAIN TREATMENT MARKET, BY INDICATION, $M (2015-2030)
Figure 38: APAC CHRONIC PAIN TREATMENT MARKET, BY APPLICATION, $M (2015-2030)
Figure 39: APAC CHRONIC PAIN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, $M (2015-2030)
Figure 40: APAC CHRONIC PAIN TREATMENT MARKET, BY END USER, $M (2015-2030)
Figure 41: APAC CHRONIC PAIN TREATMENT MARKET, BY COUNTRY, $M (2015-2030)
Figure 42: LATAM CHRONIC PAIN TREATMENT MARKET SNAPSHOT
Figure 43: LATAM CHRONIC PAIN TREATMENT MARKET, BY PRODUCT, $M (2015-2030)
Figure 44: LATAM CHRONIC PAIN TREATMENT MARKET, BY INDICATION, $M (2015-2030)
Figure 45: LATAM CHRONIC PAIN TREATMENT MARKET, BY APPLICATION, $M (2015-2030)
Figure 46: LATAM CHRONIC PAIN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, $M (2015-2030)
Figure 47: LATAM CHRONIC PAIN TREATMENT MARKET, BY END USER, $M (2015-2030)
Figure 48: LATAM CHRONIC PAIN TREATMENT MARKET, BY COUNTRY, $M (2015-2030)
Figure 49: MEA CHRONIC PAIN TREATMENT MARKET SNAPSHOT
Figure 50: MEA CHRONIC PAIN TREATMENT MARKET, BY PRODUCT, $M (2015-2030)
Figure 51: MEA CHRONIC PAIN TREATMENT MARKET, BY INDICATION, $M (2015-2030)
Figure 52: MEA CHRONIC PAIN TREATMENT MARKET, BY APPLICATION, $M (2015-2030)
Figure 53: MEA CHRONIC PAIN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, $M (2015-2030)
Figure 54: MEA CHRONIC PAIN TREATMENT MARKET, BY END USER, $M (2015-2030)
Figure 55: MEA CHRONIC PAIN TREATMENT MARKET, BY COUNTRY, $M (2015-2030)
Figure 56: PRODUCT BENCHMARKING OF KEY PLAYERS IN CHRONIC PAIN TREATMENT DRUGS MARKET
Figure 57: PRODUCT BENCHMARKING OF KEY PLAYERS IN CHRONIC PAIN TREATMENT DEVICES MARKET
Figure 58: ELI LILLY AND COMPANY - REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2020)
Figure 59: GLAXOSMITHKLINE PLC - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
Figure 60: PFIZER INC. - REVENUE SPLIT BY PRODUCT AND GEOGRAPHY (2020)
Figure 61: MEDTRONIC PLC - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2021)
Figure 62: ABBOTT LABORATORIES - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
Figure 63: BOSTON SCIENTIFIC CORPORATION - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
Figure 64: NOVARTIS AG - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
Figure 65: JOHNSON & JOHNSON - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
Figure 66: ASTRAZENECA PLC - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
Figure 67: BRISTOL-MYERS SQUIBB COMPANY - REVENUE SPLIT BY BRAND AND GEOGRAPHY (2020)
Figure 68: BECTON, DICKINSON AND COMPANY - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
Figure 69: SANOFI S.A. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
Note: Product cover images may vary from those shown
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Medtronic plc
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Novartis AG
  • Johnson & Johnson
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Becton, Dickinson and Company
  • Sanofi S.A.
Note: Product cover images may vary from those shown

Loading
LOADING...